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SUMMARY. Chagas’ disease, caused by the protozoan parasite Trypanosoma cruzi, affects 9-12 million of
people in Latin America and it is an important cause of heart disease. Although transmission has been re-
duced, an effective therapy for the infected population is lacking. New isomers nitroimidazole derivatives
[4(5)-bromo-1-phenacyl-5(4)-nitroimidazoles] were developed and their antichagasic properties were stud-
ied. Five compounds (with different substituents in their aromatic ring) displayed remarkable in vitro ac-
tivities against T. cruzi. The results demonstrated that 4(5)-bromo-1-(4-methoxiphenacyl)-2-methyl-5(4)-
nitroimidazole, 4(5)-bromo-1-(4-chlorophenacyl)-2-methyl-5(4)-nitroimidazole, and 4(5)-bromo-1-(4-
cianophenacyl)-2-methyl-5(4)-nitroimidazole have IC50 values of of 3.95, 2.3, and 1.15 μg/mL, respectively,
and show acceptable values of cytotoxicity, at concentrations below 5 μg/mL. Our results indicate that
mixtures of isomers are a potent inhibitor of T. cruzi growth. The present evidence shows very promising
results of new isomers, which emerge as strong candidates for further tests as  anti-T. cruzi agents.
